Osobitosti hiperlipoproteinemija u inzulin neovisnom dijabetesu

An open prospective study including 200 newly detected patients with NIDDM and hyperlipoproteinemia was carried out. Sixty-four patients with NIDDM were excluded from the study for failing to comply with the instructions by the researchers: loss to follow-up, switch to insulin therapy, cessation of menstrual periods, taking oral contraceptive agents, hypolipemics, diuretics or beta blockers. The control group consisted of 200 subjects with hyperlipoproteinemia and normal glucose tolerance. Patients with NIDDM were divided in two groups. The first group consisted of men (N=86), and the other of women (N=52). These two groups were further divided into subgroups: subjects below and above 50 years of age. The study aimed to determine the type and extent of changes occuring in patients with NIDDM and hyperlipidemia at the moment of optimal glycemic control, lipoprotein, apolipoprotein and leptin levels, as well as the influence of fat tissue distribution on individual lipoprotein, apolipoprotein and leptin fractions. Possible sex-related differences in particular lipoprotein, apolipoprotein and leptin fractions and the fertile age of female patients as compared to postmenopausal one, respectively, were studied. The following changes occurred at the moment of optimal glycemic control (HbA1c≤6.30%) in patients with newly detected NIDDM and hyperlipidemia: statistically significant reduction in total, HDL2 and VLDL cholesterol and triglycerides, although lipoprotein level was not optimal. HDL3 cholesterol and apo B levels were increased. Patients taking glibenclamide for glycemic control had a statistically significant increase in Lp(a) (p